EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi

Benjamin Morgan, Eleanor A Lyons iD, Amanda Handley iD, Nada Bogdanovic-Sakran, Daniel Pavlic, Desiree Witte iD, Jonathan Mandolo, Ann Turner, Khuzwayo C Jere iD, Frances Justice, Darren Suryawijaya Ong iD, Rhian Bonnici und 9 weitere

Viruses · 2024

DOI: 10.3390/v16091488 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Viruses, 2024. Verfasst von Benjamin Morgan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Enteric Diseases, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia. Hauptthemen laut MEDLINE: Rotavirus Vaccines, Antibodies, Viral, Rotavirus Infections, Rotavirus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, Australian Trade and Investment Commission, Australian Tropical Medicine Commercialisation Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (p < 0.005) and 3 (p < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rotavirus VaccinesAntibodies, ViralRotavirus InfectionsRotavirusImmunoglobulin AImmunoglobulin GHumansMalawiFemaleInfantInfant, NewbornImmunization ScheduleAdultImmunity, Maternally-AcquiredVaccine EfficacyFecesMaleVaccines, AttenuatedVaccinationYoung Adult

Stichwörter der Autor:innen

RV3-BB vaccinematernal antibodiesrotavirus vaccine

Substanzen

Rotavirus VaccinesAntibodies, ViralImmunoglobulin AImmunoglobulin GRV3 rotavirus vaccineVaccines, Attenuated

Autor:innen und Institutionen

  • Enteric Diseases, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
  • Medicines Development for Global Health, Melbourne, VIC 3001, Australia.
  • Malawi Liverpool Welcome Trust Programme, Blantyre P.O. Box 30096, Chichi, Malawi.
  • Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7ZX, UK.
  • Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.
  • Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville, VIC 3052, Australia.

ORCID-Profile: Eleanor A Lyons, Amanda Handley, Desiree Witte, Khuzwayo C Jere, Darren Suryawijaya Ong, Celeste M Donato, Naor Bar-Zeev, Julie E Bines

Förderung

  • Bill and Melinda Gates Foundation
  • Australian Trade and Investment Commission
  • Australian Tropical Medicine Commercialisation Grant
  • Victorian Government’s Operational Infrastructure Support Program

Zitieren

APA

Morgan, B., Lyons, E. A., Handley, A., Bogdanovic-Sakran, N., Pavlic, D., Witte, D., Mandolo, J., Turner, A., Jere, K. C., Justice, F., Ong, D. S., Bonnici, R., Boniface, K., Donato, C. M., Mpakiza, A., Meyer, A., Bar-Zeev, N., Iturriza-Gomara, M., Cunliffe, N. A., …, & Bines, J. E. (2024). Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi. Viruses. https://doi.org/10.3390/v16091488

Vancouver

Morgan B, Lyons EA, Handley A, Bogdanovic-Sakran N, Pavlic D, Witte D, et al. Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi. Viruses. 2024. doi:10.3390/v16091488

BibTeX
@article{Morgan2024,
  author = {Morgan, Benjamin and Lyons, Eleanor A and Handley, Amanda and Bogdanovic-Sakran, Nada and Pavlic, Daniel and Witte, Desiree and Mandolo, Jonathan and Turner, Ann and Jere, Khuzwayo C and Justice, Frances and Ong, Darren Suryawijaya and Bonnici, Rhian and Boniface, Karen and Donato, Celeste M and Mpakiza, Ashley and Meyer, Anell and Bar-Zeev, Naor and Iturriza-Gomara, Miren and Cunliffe, Nigel A and Danchin, Margaret and Bines, Julie E},
  title = {Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16091488}
}
Kostenlos starten →